Provided are an ophthalmic composition comprising an amino amantadine mononitrate compound in a mass/volume ratio of 0.001-5% and an application of the ophthalmic composition in preparing a drug for preventing or treating glaucoma, high intraocular pressure, or an eye disease with retinal ganglion cell damage.